Insilico Medicine names Halle Zhang as VP of clinical development oncology

Insilico Medicine (3696.HK) appointed Halle Zhang, PhD (Med), as Vice President of Clinical Development for Oncology, the company announced February 6. Zhang will report to Co-Chief Executive Officer and Chief Scientific Officer Feng Ren and be based in the Cambridge, Massachusetts office.

Zhang will lead global clinical development strategy and execution for Insilico's oncology portfolio across early and late-stage programs. She brings more than 20 years of experience in oncology clinical development from academia, biotechnology and pharmaceutical companies.

Most recently, Zhang served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb. She managed global development strategy across multiple solid tumor indications including lung, breast, melanoma, gastric, colorectal, bladder and head and neck cancers.

Zhang previously held senior clinical development roles at Infinity Pharmaceuticals and BioMed Valley Discoveries. She began her career in academic research and clinical operations at Harvard Medical School, leading NIH-sponsored clinical trials. She holds a PhD in Medicine and MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth.

Insilico's oncology programs have advanced several compounds to Phase I trials. In January 2025, ISM6331, a pan-TEAD inhibitor, completed first patient dosing in a Phase I trial for mesothelioma and other solid tumors. In June 2025, ISM3412, a MAT2A inhibitor, completed first patient dosing in patients with locally advanced and metastatic solid tumors.

The company has partnerships with Servier valued at up to $888 million and with Menarini Group totaling up to $550 million. Insilico received a $3 million milestone payment from Menarini in July 2025 and a $5 million milestone upon dosing the first patient in the Phase I trial of MEN2501.

You May Also Be Interested In

• Peraso CFO James Sullivan resigns effective October 2026
• Lithium Americas VP of corporate development to retire in September
• Amrize names Mario Gross as Building Envelope president